Blog
RSS FeedPosted by Michael Wonder on 19 Sep 2019
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
18 September 2019 - In this study, the investigators examined the characteristics of randomised controlled trials that supported approval of cancer ...
Posted by Michael Wonder on 12 Sep 2019
Why Canada can't be America's pharmacy
11 September 2019 - Canada doesn't have enough drugs to share, and it doesn't want that role. ...
Posted by Michael Wonder on 12 Sep 2019
New rules will keep the best medications from desperate Canadians
12 September 2019 - One reaction to recent amendments to the rules of the federal Patented Medicine Prices Review Board, ...
Posted by Michael Wonder on 12 Sep 2019
Big Pharma is abusing patents, and it's hurting Americans
12 September 2019 - The American patent system has, since our nation's founding, served as a cornerstone of innovation. But ...
Posted by Michael Wonder on 12 Sep 2019
Ardelyx receives FDA approval for Ibsrela (tenapanor), an NHE3 sodium transport inhibitor, for the treatment of irritable bowel syndrome with constipation
12 September 2019 - Approval supported by two Phase 3 trials demonstrating a statistically significant reduction in constipation and abdominal pain ...
Posted by Michael Wonder on 12 Sep 2019
Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
12 September 2019 - GlaxoSmithKline today announced that the US FDA has approved Nucala (mepolizumab) for use in children as young ...
Posted by Michael Wonder on 12 Sep 2019
Aspen's drug to prevent preterm birth approved by FDA
13 September 2019 - The U.S. Food and Drug Administration (FDA) has approved Aspen Pharmacare’s hydroxyprogesterone caproate, which is used to ...
Posted by Michael Wonder on 12 Sep 2019
ICER publishes evidence report on additive cardiovascular disease therapies
12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...
Posted by Michael Wonder on 12 Sep 2019
SMC U-turn for Vertex’s CF drugs
12 September 2019 - Vertex has announced that following a change of heart by the SMC, eligible cystic fibrosis patients ...
Posted by Michael Wonder on 12 Sep 2019
Be grateful for your health insurance company
11 September 2019 - It has the thankless job of saying ‘no.’ But policing claims allows you to get better benefits. ...
Posted by Michael Wonder on 12 Sep 2019
Kiwi cancer survival rates improving at slower rate than comparable countries, study shows
12 September 2019 - New Zealand is near the bottom for cancer survival compared to six other countries with similar ...
Posted by Michael Wonder on 12 Sep 2019
When are RCTs required for breakthrough drugs, HDEs? JAMA study investigates
11 September 2019 - A new study in JAMA Network Open finds that drugs and medical devices approved by the ...
Posted by Michael Wonder on 11 Sep 2019
NICE publishes its 600th technology appraisal guidance
12 September 2019 - The guidance relates to the use of pembrolizumab in combination with carboplatin and paclitaxel on the ...
Posted by Michael Wonder on 11 Sep 2019
Immunotherapy a groundbreaking new cancer treatment, but prohibitively expensive
10 September 2019 - Dave Roberts is fighting for his life, and his doctor says there is only one option ...
Posted by Michael Wonder on 11 Sep 2019
We need to make biosimilars easier to get
11 September 2019 - If potential biosimilar manufacturers can’t get their product to market, they won’t proceed with development. ...
Posted by Michael Wonder on 11 Sep 2019
Children with rare inherited condition to benefit from drug through managed access agreement
11 September 2019 - It is estimated that in the UK there are around 30 to 50 children living with the ...